Among 150 samples from adults with newly diagnosed AML (patient characteristics are shown in Supporting information, Table S1), 108 (72%) were tested CD34 positive (defined by at least 2% CD34‐expressing leukemic blasts within the bulk leukemia population to exclude major contamination of this population by normal HSPCs, which may comprise a population of up to one percent also at AML diagnosis). The gene discussed is CD34; the disease is acute myeloid leukemia.